Claims for Patent: 6,030,775

Summary for Patent: 6,030,775

Title:	Methods and reagents for typing HLA Class I genes
Abstract:	Consensus sequences of introns 1, 2 and 3 from the majority of HLA-A, -B and -C allotypes are identified and used to develop primers located within introns 1 and 3 of the HLA-A, HLA-B and HLA-C genes. These primers are suitable for locus-specific amplification of the entirety of exons 2 and 3, i.e., the portion of these of genes most suitable for use in typing of HLA-A, HLA-B and HLA-C. These primers are also suitable for use as sequencing primers to determine the HLA alleles in sequence-based HLA typing. Thus, the primers can be used for testing a sample to determine the HLA-A, -B or -C type of the sample by treating the tissue sample to obtain nucleic acid polymers suitable for amplification; combining the nucleic acid polymers with a first primer which is complementary to a portion of intron 1 or intron 3 of the HLA gene, and a second primer which is complementary to some other portion of the HLA gene under conditions suitable for amplification to obtain an amplified product; and evaluating the amplified product to determine the allelic type of the HLA-A, HLA-B or HLA-C genes. Preferably, at least one of the amplification primers has a sequence which provides locus-specific amplification.
Inventor(s):	Yang; Soo Young (New York, NY), Cereb; Nezih (New York, NY)
Assignee:
Application Number:	08/577,081
Patent Claims:	1. A method for testing a tissue sample to determine the allelic type of an HLA Class I gene in the sample, said HLA Class I gene being selected from among HLA-A, HLA-B and HLA-C genes comprising the steps of (a) treating the tissue sample to obtain nucleic acid polymers suitable for amplification; (b) combining the nucleic acid polymers with a first primer which hybridizes with a portion of intron 1 or intron 3 of the HLA Class I gene, and a second primer which hybridizes with a different portion of the HLA Class I gene conditions suitable for amplification to obtain an amplified product, wherein the first primer and the second primer flank a region including at least one site of allelic variation in at least one of exons 2 or 3 of the HLA Class I gene and wherein the first primer is a locus specific primer which hybridizes with intron 1 or intron 3 of only one of the HLA Class I genes; and (c) evaluating the amplified product to determine the allelic type of the HLA-Class I gene. 2. The method of claim 1, wherein the first primer hybridizes with intron 1 and the second primer hybridizes with intron 3 of the selected HLA Class I gene. 3. The method of claim 2, wherein at least one of the first primer and the second primer specifically hybridizes with the selected HLA Class I gene to provide locus-specific amplification. 4. The method of claim 2, wherein the HLA Class I gene is an HLA-A gene, and the first primer is an oligonucleotide which is complementary to or has the same sequence as a portion of SEQ ID No.: 1. 5. The method of claim 2, wherein the HLA Class I gene is an HLA-A gene, and the first primer is an oligonucleotide which is complementary to or has the same sequence as a portion of SEQ ID No.: 3. 6. The method of claim 2, wherein the HLA Class I gene is an HLA-B gene, and the first primer is an oligonucleotide which is complementary to or has the same sequence as a portion of SEQ ID No.: 4. 7. The method of claim 2, wherein the HLA Class I gene is an HLA-B gene, and the first primer is an oligonucleotide which is complementary to or has the same sequence as a portion of SEQ ID No.: 6. 8. The method of claim 2, wherein the HLA Class I gene is an HLA-C gene, and the first primer is an oligonucleotide which is complementary to or has the same sequence as a portion of SEQ ID No.: 7. 9. The method of claim 2, wherein the HLA Class I gene is an HLA-C gene, and the first primer is an oligonucleotide which is complementary to or has the same sequence as a portion of SEQ ID No.: 9. 10. The method of claim 1, wherein the amplified product is evaluated using sequence specific oligonucleotide probes which hybridize selectively to known alleles of the HLA gene. 11. The method of claim 1, wherein the amplified product is evaluated by direct sequencing. 12. The method of claim 11, wherein the amplified product is sequenced using a sequencing primer which hybridizes to all of the classical HLA Class I genes. 13. The method of claim 1, wherein the first amplification primer is any of the primers identified by SEQ ID Nos.: 10-14 and 23-38. 14. The method of claim 1, further comprising the step of testing a portion of the nucleic acid polymers from the sample to determine the type of at least one non-classical HLA Class I genes. 15. The method of claim 12, wherein the step of testing the portion of the nucleic acid polymers includes the steps of combining the portion of the nucleic acid polymers with a first non-classical primer which specifically hybridizes with a portion of the non-classical HLA Class I gene, and a second non-classical primer which hybridizes with a different portion of the non-classical HLA Class I gene under conditions suitable for amplification to obtain an amplified non-classical product; and (c) evaluating the amplified non-classical product to determine the allelic type of the non-classical HLA-Class I gene. 16. The method of claim 15, wherein the first or second non-classical primer is any of the primers identified by SEQ ID Nos.: 41, 42, 45, 47, 48, 50, 51, 53, 54, and 56 to 61. 17. A method for preparing an amplification primer pair for locus-specific amplification of exons 2 and 3 of a selected classical HLA Class I gene comprising the steps of: (a) evaluating the aligned sequences of intron 1 of the classical HLA Class I gene to select an intron 1 sequence of from 10 to 40 bases which differs in the selected gene from unselected classical HLA Class I genes; (b) scanning the known sequences of the selected and unselected classical HLA Class I genes to determine if the selected intron 1 sequence is repeated elsewhere within the genes and selecting a new intron 1 sequence if repetition is found; (c) evaluating the aligned sequences of intron 3 of the classical HLA Class I gene to select an intron 3 sequence of from 10 to 40 bases which differs in the selected gene from unselected classical HLA Class I genes; (d) scanning the known sequences of the selected and unselected classical HLA Class I genes to determine if the selected intron 3 sequence is repeated elsewhere within these genes and selecting a new intron 3 sequence if repetition is found; and (e) synthesizing a pair of primers having the sequences of the selected intron 1 and intron 3 sequences. 18. The method of claim 17, further comprising the step of performing a test amplification using the synthesized primers and testing the amplification products with sequence specific probes to confirm locus specificity. 19. A kit for testing a tissue sample to determine the allelic type of an HLA Class I gene in the sample comprising, in packaged combination, at least one pair of amplification primers, said pair of amplification primers including a first primer which hybridizes with a portion of intron 1 or intron 3 of the HLA Class I gene and a second primer which hybridizes with a different portion of the HLA Class I gene under conditions suitable for amplification to obtain an amplified product, wherein the first primer and the second primer flank a region including at least one site of allelic variation in at least one of exons 2 or 3 of the HLA Class I gene and wherein the first primer is a locus specific primer which hybridizes with intron 1 or intron 3 of only one of the HLA Class I genes. 20. The kit of claim 19, wherein the first primer is a locus-specific primer which specifically hybridizes with one and only one of the HLA Class I genes. 21. The kit of claim 20, wherein the HLA Class I gene is an HLA-A gene, and the first primer specifically hybridizes with or is the same as a continuous portion of SEQ ID NO.: 1, 2 or 3. 22. The kit of claim 20, wherein the HLA Class I gene is an HLA-B gene, and the first primer specifically hybridizes with or is the same as a continuous portion of SEQ ID NO.: 4, 5 or 6. 23. The kit of claim 20, wherein the HLA Class I gene is an HLA-C gene, and the first primer specifically hybridizes with or is the same as a continuous portion of SEQ ID NO.: 7, 8 or 9. 24. The kit of claim 20, further comprising at least one separate container containing a sequence-specific oligonucleotide probe which hybridizes selectively to a known allele of the HLA gene. 25. A method for testing a tissue sample to determine the allelic type of an HLA Class I gene in the sample, said HLA Class I gene being selected from among the non-classical HLA genes comprising the steps of (a) treating the tissue sample to obtain nucleic acid polymers suitable for amplification; (b) combining the nucleic acid polymers with a locus-specific first primer which specifically hybridizes with a portion of the non-classical HLA Class I gene, and a second primer which hybridizes with a different portion of the non-classical HLA Class I gene under conditions suitable for amplification to obtain an amplified non-classical product; and (c) evaluating the amplified non-classical product to determine the allelic type of the non-classical HLA Class I gene. 26. The method of claim 25, wherein the locus-specific first primer is any of the primers identified by SEQ ID Nos.: 41, 42, 45, 47, 48, 50, 51, 53, 54, and 57 to 61. 27. The method of claim 25, wherein the second primer has the sequence given by SEQ ID No.: 56.

Details for Patent 6,030,775

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26